4//SEC Filing
OrbiMed Capital GP V LLC 4
Accession 0000947871-20-000944
CIK 0001422142other
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 5:04 PM ET
Size
13.9 KB
Accession
0000947871-20-000944
Insider Transaction Report
Form 4
ORBIMED ADVISORS LLC
Director10% Owner
Transactions
- Sale
Common Stock
2020-12-08$1.96/sh−21,400$41,944→ 0 total(indirect: See Footnotes) - Exercise of In-Money
Stock Option (Right to Buy)
2020-12-08−21,400→ 0 total(indirect: See Footnotes)Exercise: $0.96Exp: 2029-06-28→ Common Stock (21,400 underlying) - Exercise of In-Money
Common Stock
2020-12-08$0.96/sh+21,400$20,544→ 21,400 total(indirect: See Footnotes)
Holdings
- 5,193,946(indirect: See Footnotes)
Common Stock
OrbiMed Capital GP V LLC
Director10% Owner
Transactions
- Exercise of In-Money
Stock Option (Right to Buy)
2020-12-08−21,400→ 0 total(indirect: See Footnotes)Exercise: $0.96Exp: 2029-06-28→ Common Stock (21,400 underlying) - Exercise of In-Money
Common Stock
2020-12-08$0.96/sh+21,400$20,544→ 21,400 total(indirect: See Footnotes) - Sale
Common Stock
2020-12-08$1.96/sh−21,400$41,944→ 0 total(indirect: See Footnotes)
Holdings
- 5,193,946(indirect: See Footnotes)
Common Stock
Footnotes (5)
- [F1]This shares are held by Chau Khuong ("Khuong"). OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of OrbiMed Capital GP V LLC ("GP V"), which is the general partner of OrbiMed Private Investments V, LP ("OPI V"). Pursuant to an agreement with OrbiMed Advisors and GP V, Khuong is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V.
- [F2]Each of the GP V, OrbiMed Advisors, and Khuong disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F3]The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.94 to $2.00. The Reporting Persons
- [F4]These Shares are held of record by OPI V. By virtue of the relationships described in footnote 1, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI V and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, and Sven H. Borho, each of whom disclaims beneficial ownership of the Shares held by OPI V.
- [F5]This option was granted to Khuong on June 18, 2019 and vested on the first anniversary of the grant date. Pursuant to an agreement with OrbiMed Advisors and GP V, Khuong is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OPI V.
Documents
Issuer
Aerpio Pharmaceuticals, Inc.
CIK 0001422142
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001615374
Filing Metadata
- Form type
- 4
- Filed
- Dec 9, 7:00 PM ET
- Accepted
- Dec 10, 5:04 PM ET
- Size
- 13.9 KB